

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



30th May 2025

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

Scrip Code – 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra – Kurla Complex
Bandra (E)

Mumbai – 400 051.

Scrip Code–
APOLLOHOSP
ISIN INE437A01024

Dear Sirs,

Re: Intimation of outcome of Board Meeting under Regulations 30, 33, and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("SEBI Listing Regulations")

Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our letters dated March 24, 2025, and May 5, 2025, we wish to inform you that the Board of Directors ('Board') of the Company at its meeting held today, i.e., May 30, 2025, inter alia, transacted the following items of business:

1. Financial Results

- a. Approval of the Audited Standalone financial results of the Company for the quarter and year ended 31st March 2025 along with the Audit Report on the standalone financial statements.
- b. Approval of the Audited Consolidated financial results of the Company for the quarter and year ended 31st March 2025 along with the Audit Report on the consolidated financial statements.
- c. Declaration that the statutory auditors have issued audit reports with unmodified opinion on financial statements.
- d. The above said documents are being posted on the website of the Company i.e., www.apollohospitals.com.
- e. The financial results will also be published in the newspapers, in the format prescribed under Regulation 47 of the Listing Regulations.

The said audited financial results for the financial year ended March 31, 2025 and the auditors' reports thereon are attached herewith – Annexure - 1.

IS/ISO 9001 : 2000

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com



2. Dividend

Recommended a final dividend of ₹10/- per Equity Share (200%) of the face value of ₹5/- per share to the shareholders of the Company for FY2024-25.

The dividend recommended by the Board of Directors of the Company is subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM) of the Company.

The Board of Directors at its Meeting held on February 10, 2025 declared an Interim Dividend of ₹9/- per equity share of face value of ₹5/- each, (180%) on the paid up equity capital of the Company for the financial year 2024-2025.

The Interim Dividend on equity shares of the Company as declared by the Board of Directors was paid on February 28, 2025

The total dividend for the financial year 2024-2025, including the proposed final dividend, amounts to ₹19/- per equity share (380%) amounting to ₹ 2,731.90 million.

3. Convening Annual General Meeting

The Annual General Meeting of the Company is scheduled to be held on **Friday, 29th August 2025 through video conferencing and other audio-visual means.**

4. Fixation of Record Date

The Board has fixed the record date as Tuesday, 19th August 2025 for the purpose of determining the names of the shareholders who are entitled for the final dividend and also for the purpose of the Annual General Meeting.

5. Dividend payment date

The dividend, if declared at the Annual General Meeting will be paid on or before 10th September 2025.

6. Appointment of Secretarial Auditors

The Board, based on the recommendation of the Audit Committee, has approved the appointment of M/s. Lakshmmi Subramanian & Associates, Practising Company Secretaries, as Secretarial Auditors of the Company for a period of five consecutive years commencing from FY 2025-26 till FY 2029-30, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting.

Additional information as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations is enclosed as Annexure 2



7. Re-appointment of Executive Directors

Based on the recommendations of the Nomination and Remuneration Committee, the Board approved the re-appointment of following Executive Directors for a further period of five years with effect from 3rd February 2026, subject to approval of members at the ensuing Annual General Meeting.

- (a) Ms. Preetha Reddy (DIN 00001871), Executive Vice Chairperson
- (b) Ms. Suneeta Reddy (DIN 00001873), Managing Director and
- (c) Ms. Sangita Reddy (DIN 00006285), Joint Managing Director

The aforesaid Executive Directors being re-appointed are not debarred from holding the office as a Director by virtue of any SEBI Order or any other authority.

The details as required under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the relevant Circular issued thereunder are provided in the enclosed Annexure - 3.

8. Re-appointment of Independent Director

Mr. Som Mittal (DIN 00074842) is an Independent Director of the Company, whose first five-year term as an Independent Director expires on 20th July 2026.

Pursuant to the provisions of Section 149 of the Companies Act, 2013 and Regulation 16 & 25 of the SEBI Listing Regulations, 2015 and based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the proposal for re-appointment of Mr.Som Mittal as an Independent Director for a second term of five consecutive years from 21st July 2026 to 20th July 2031, subject to approval of the Shareholders of the Company by way of special resolution at the ensuing Annual General Meeting.

We hereby inform that Mr. Som Mittal is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority and therefore, are not disqualified to be re-appointed as Independent Director.

The details as required under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the relevant Circular issued thereunder are provided in the enclosed Annexure - 4.

9. Investment Proposals

The Board has approved the following proposals.

- A. Purchase of a land parcel admeasuring 2.53 acres at Sarjapur, Bengaluru for setting up a 500-bed greenfield multi-speciality hospital at an estimated overall cost of Rs 944 crores.

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



- B. Acquire an existing operating hospital asset (leased facility) located in the vicinity of the above – 200 Total beds (160 census beds) – to be commissioned within 90-120 days post-acquisition. The overall estimated cost of acquiring the existing hospital would be Rs 285 crores.

The details as required under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the relevant Circular issued thereunder are provided in the enclosed Annexure - 5.

10. Disclosure Requirements for Large Corporates

Pursuant to SEBI Circular No. SEBI/HO/DDHS/DDHSRACPODI/P/CIR/2023/ 172 dated October 19, 2023, we hereby furnish the following details for the financial year ended 31st March 2025.

Sl.No.	Particulars	Amount (Rs. in crores)
1	Outstanding Qualified Borrowings at the start of the financial year	Rs.1,956.00
2	Outstanding Qualified Borrowings at the end of the financial year	Rs.1,783.00
3	Credit rating (highest in case of multiple ratings)	Credit Rating : AA + Credit Rating Agency : CRISIL Ratings Limited Credit Rating : AA + Credit Rating Agency : India Ratings & Research Pvt Ltd
4	Incremental borrowing done during the year	Nil
5	Borrowings by way of issuance of debt securities during the year	Nil

The Board meeting commenced at 12.15 p.m (IST) and concluded at p.m. (IST).

Kindly take on record the same.

Thanking You

Yours faithfully
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN
Sr. VICE PRESIDENT – FINANCE
AND COMPANY SECRETARY



IS/ISO 9001:2008

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Standalone Balance Sheet

(Rs. in Million)

Particulars	As at 31-Mar-25 Audited	As at 31-Mar-24 Audited
ASSETS		
Non-current assets		
(b) Right-of-use assets	49,105	47,096
(c) Capital work-in-progress	13,285	12,612
(d) Other intangible assets	2,940	1,725
(e) Intangible assets under development	1,091	608
(f) Financial assets	125	272
(i) Investments	24,790	19,377
(ii) Loans	4,291	2,446
(iii) Other financial assets	1,530	1,789
(g) Income tax asset (net)	290	729
(h) Other non-current assets	1,092	647
Total non-current assets	98,539	87,301
Current assets		
(a) Inventories	1,266	1,187
(b) Financial assets		
(i) Investments	14,317	6,835
(ii) Trade receivables	8,148	8,083
(iii) Cash and cash equivalents	2,332	2,761
(iv) Bank balances other than (iii) above	3,609	661
(v) Loans	221	791
(vi) Other financial assets	1,723	13,673
(c) Contract assets	1,080	878
(d) Other current assets	2,488	1,882
Total current assets	35,184	36,751
Total assets	133,723	124,052
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	719	719
(b) Other equity	86,623	76,390
Total equity	87,342	77,109
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	15,535	17,855
(ii) Lease liabilities	12,782	11,563
(iii) Other financial liabilities	12	23
(b) Deferred tax liabilities (net)	3,632	3,764
(c) Other non-current liabilities	13	36
Total non-current liabilities	31,974	33,241
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	2,297	1,702
(ii) Lease liabilities	282	1,098
(ii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises; and	627	586
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	7,600	6,989
(iv) Other financial liabilities	1,002	1,236
(b) Other current liabilities	1,323	1,078
(c) Provisions	1,276	1,013
Total current liabilities	14,407	13,702
Total liabilities	46,381	46,943
Total equity and liabilities	133,723	124,052

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of Standalone Financial Results for the three months and the year ended March 31, 2025

(Rs. in Million)

Particulars	Three months ended 31/03/2025	Preceding three months ended 31/12/2024	Corresponding three months ended 31/03/2024	Year to date figures for current period ended 31/03/2025	Previous year ended 31/03/2024
	Refer Note 2	Unaudited	Refer Note 2	Audited	Audited
1 Income					
(a) Revenue from operations	20,753	20,548	18,946	82,021	72,738
(b) Other income	916	1,079	460	3,477	1,799
Total Income (a + b)	21,669	21,627	19,406	85,498	74,537
2 Expenses					
(a) Cost of materials consumed	5,620	5,693	5,266	22,484	19,990
(b) Employee benefits expense	4,102	3,935	3,839	15,968	14,252
(c) Finance costs	631	620	687	2,540	2,498
(d) Depreciation and amortisation expenses	1,298	1,084	1,153	4,494	3,990
(e) Other expenses	5,818	5,802	5,337	23,127	20,521
Total Expenses	17,469	17,134	16,282	68,613	61,251
3 Profit before tax (1) - (2)	4,200	4,493	3,124	16,885	13,286
4 Tax expense					
Current tax	992	1,051	544	4,055	3,216
Deferred tax	(126)	26	192	(133)	(35)
5 Profit after tax for the period / year (3) - (4)	3,334	3,416	2,388	12,963	10,105
6 Other comprehensive income/(loss)					
Items that will not be reclassified to profit or loss					
(a) Remeasurement gains/(losses) on defined benefit plans	2	(33)	4	3	(114)
Income tax relating to items that will not be reclassified to profit or loss	(0)	8	(1)	(1)	29
Total other comprehensive income/ (loss)	1	(25)	3	2	(85)
7 Total comprehensive income for the period/year (5) + (6)	3,335	3,391	2,391	12,965	10,020
8 Paid-up equity share capital (Face value Rs.5/- per share)				719	719
9 Reserves (excluding Revaluation reserves)				86,623	76,390
10 Earnings per equity share of Rs.5/- each					
Basic and diluted earnings per share for the period/year (Rs.)	*23.18	*23.76	*16.61	90.15	70.28
11 Additional Information :-					
Earnings before finance costs, tax, depreciation and amortization, other income, exceptional items (EBITDA) (refer foot note)	5,213	5,118	4,504	20,442	17,975

*Not annualised

Foot note:

1 The Company has presented EBITDA additionally as part of standalone financial results.

APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
 Managing Director

Apollo Hospitals Enterprise Limited

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Statement of Standalone Cash Flows

(Rs. in Million)

PARTICULARS	For the year ended March 31, 2025 (Audited)	For the year ended March 31, 2024 (Audited)
A. Cash flow from Operating Activities		
Profit for the year	12,963	10,105
Adjustments for:		
Depreciation and amortisation expenses	4,494	3,990
Income Tax expense	4,055	3,181
(Profit)/loss on sale of property plant & equipment	6	(14)
Profit on sale of investments (net)	(132)	(90)
Impairment in value of investment	20	-
Gain on fair valuation of mutual funds	(633)	(284)
Gain on fair valuation of equity investments	(7)	(6)
Finance costs	2,540	2,498
Interest from banks/others	(845)	(367)
Dividend on non-current equity investments	(1,766)	(1,018)
Expected credit loss on trade receivables	273	354
Unrealised foreign exchange (gain)/loss (net)	4	1
Provision written back	-	(2)
Operating Profit before working capital changes	20,972	18,348
Adjustments for (increase)/decrease in operating assets		
Inventories	(79)	(204)
Trade receivables	(337)	(238)
Other financial assets	265	(3,589)
Other assets	(571)	(264)
	(722)	(4,295)
Adjustments for increase/(decrease) in operating liabilities		
Trade payables	647	1,245
Other financial liabilities	(216)	(235)
Provisions	266	129
Other liabilities	222	22
	919	1,161
Cash generated from operations	21,169	15,214
Net income tax paid	(3,750)	(3,300)
Net cash generated from operating activities (A)	17,419	11,914
B. Cash flow from Investing Activities		
Purchase of property plant & equipment, CWIP & intangibles	(8,582)	(6,210)
Proceeds from sale of property plant & equipment	137	11
Consideration received from Apollo HealthCo Limited on reorganisation of pharmacy distribution business	12,008	-
Loans given	(3,130)	(242)
Repayments received towards loans	1,855	164
Purchase of non-current investments	(5,426)	(143)
Purchase of current investments	(24,868)	(11,655)
Proceeds from sale of current investments	18,151	8,110
Proceeds from sale of non-current investments	-	57
Proceeds from/(Investment in) Bank Deposits	(2,948)	348
Interest received	580	189
Dividend received from subsidiaries and associates	1,766	1,018
Net cash used in Investing Activities (B)	(10,457)	(8,353)
C. Cash flow from Financing Activities		
Proceeds from borrowings	-	4,643
Payments towards lease liability	(1,102)	(1,003)
Repayment of borrowings	(1,726)	(2,691)
Finance costs	(1,831)	(1,762)
Dividends paid	(2,732)	(2,157)
Net cash used in Financing Activities (C)	(7,391)	(2,970)
Net Increase/(decrease) in cash and cash equivalents (A+B+C) = (D)	(429)	591
Cash and cash equivalents at the beginning of the year (E)	2,761	2,170
Cash and cash equivalents at the end of the year (D) +(E)	2,332	2,761

For APOLLO HOSPITALS ENTERPRISE LTD

Suneeta Reddy
SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited
Regd. Office: No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-Tamil Nadu

NOTES TO THE STATEMENT OF STANDALONE FINANCIAL RESULTS:

1. The standalone financial results ("the Statement") of Apollo Hospitals Enterprise Limited ("the Company") for the three months and year ended March 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on May 29, 2025 and May 30, 2025 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the standalone financial results for the three months ended March 31, 2025 and have expressed an unmodified audit opinion on the financial results for the year ended March 31, 2025.
2. The standalone financial results for the three months ended March 31, 2025 and March 31, 2024 are the balancing figures between the audited standalone figures for the respective years ended on those dates and the unaudited year to date standalone figures for the nine months ended December 31, 2024 and December 31, 2023 respectively, which were subject to limited review.
3. The statement has been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.
4. The Company's business activity primarily falls within a single reportable business segment namely "Healthcare Services" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind As 108- "Segment Reporting".
5. The Board declared an interim dividend of Rs.9.00 per share (180%) of face value of Rs.5/- each for the financial year 2024-2025. The record date for the payment was February 15, 2025 and the same was paid on February 28, 2025.
6. The Board recommended a final dividend for the year ended March 31, 2025 of Rs.10/- (200%) per equity share of face value of Rs.5/- each subject to the approval of the members at the forthcoming Annual General Meeting of the Company. The record date for the purpose of the payment of final dividend is 19th August 2025. The dividend will be paid on or before 10th September 2025.
7. CRISIL Ratings Limited has reaffirmed its rating on the Company's long term bank facilities (credit facilities) at CRISIL AA+/Stable and short term (working capital) facilities at CRISIL A1+.

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited
Regd. Office: No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-Tamil Nadu

8. India Ratings and Research' (Ind-Ra), a Fitch Group Company has affirmed its rating on the Company's term loans facility as 'IND AA+ indicating stable outlook.
9. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com).

For **APOLLO HOSPITALS ENTERPRISE LIMITED**

Place: Chennai
Date: May 30, 2025

Dr. Prathap C Reddy
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2025 and (b) reviewed the Standalone Financial Results for the three months ended March 31, 2025 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the three months and Year Ended March 31, 2025" of **Apollo Hospitals Enterprise Limited** ("the Company"), ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2025:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the three months ended March 31, 2025

With respect to the Standalone Financial Results for the three months ended March 31, 2025, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the three months ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.



Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2025 has been compiled from the related audited standalone financial information. This responsibility includes the preparation and presentation of the Standalone Financial Results for the three months and year ended March 31, 2025 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2025 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.

M



Deloitte Haskins & Sells LLP

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the three months ended March 31, 2025

We conducted our review of the Standalone Financial Results for the three months ended March 31, 2025 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

- The Statement includes the results for the three months ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.



Place: Chennai
Date: May 30, 2025

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)


Nachiappan Subramanian
Partner
(Membership No. 218727)
(UDIN: 25218727BMOEIQ1578)

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Consolidated Balance Sheet

(Rs. in Million)

Particulars	As at 31-Mar-25 Audited	As at 31-Mar-24 Audited
ASSETS		
Non-current assets		
(a) Property, plant and equipment	73,504	65,662
(b) Right Of use asset	24,653	19,743
(c) Capital work-in-progress	7,710	8,447
(d) Investment property	28	34
(e) Goodwill	10,305	10,123
(f) Other intangible assets	1,392	1,077
(g) Intangible assets under development	1,500	281
(h) Financial assets		
(i) Investments in equity accounted investee	2,241	1,984
(ii) Investments	8,304	1,037
(iii) Loans	272	66
(iv) Other financial assets	2,126	2,525
(i) Deferred tax assets	131	109
(j) Income tax assets (net)	2,085	2,424
(k) Other non-current assets	2,034	1,222
Total non-current assets	136,285	114,734
Current assets		
(a) Inventories	4,808	4,598
(b) Financial assets		
(i) Investments	14,323	6,840
(ii) Trade receivables	30,161	25,149
(iii) Cash and cash equivalents	5,781	5,055
(iv) Bank balances other than (iii) above	7,821	4,283
(v) Loans	51	49
(vi) Other financial assets	1,822	1,659
(c) Contract assets	1,722	1,459
(d) Other current assets	3,800	3,705
Total current assets	70,289	52,797
Total assets	206,574	167,531
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	719	719
(b) Other equity	81,404	68,635
Equity attributable to owners of the Company	82,123	69,354
Non-controlling interests	4,406	3,851
Total equity	86,529	73,205
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	44,170	22,356
(ii) Lease liabilities	24,139	19,814
(iii) Other financial liabilities	313	103
(b) Provisions	886	732
(c) Deferred tax liabilities	4,580	4,498
(d) Other non-current liabilities	168	178
Total non-current Liabilities	74,256	47,681
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	8,582	9,263
(ii) Lease liabilities	1,752	1,893
(iii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises; and	808	848
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	21,597	22,838
(iv) Other financial liabilities	8,598	7,987
(b) Other current liabilities	2,643	2,369
(c) Provisions	1,793	1,434
(d) Current tax liabilities	16	13
Total current liabilities	45,789	46,645
Total liabilities	120,045	94,326
Total equity and liabilities	206,574	167,531

For APOLLO HOSPITALS ENTERPRISE LTD

Suneeta Reddy

SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com

Website: www.apollohospitals.com

Statement of Consolidated Financial Results for the three months and the year ended March 31, 2025

(Rs. in Million)

Particulars	Three months ended 31/03/2025	Preceding three months ended 31/12/2024	Corresponding three months ended 31/03/2024	Year to date figures for current period ended 31/03/2025	Previous year ended 31/03/2024
	Refer Note 2	Unaudited	Refer Note 2	Audited	Audited
1 Income					
(a) Revenue from operations	55,922	55,269	49,439	217,940	190,592
(b) Other income	611	638	281	2,003	1,063
Total Income (a + b)	56,533	55,907	49,720	219,943	191,655
2 Expenses					
(a) Cost of materials consumed	6,944	6,256	6,375	27,544	24,541
(b) Purchases of stock-in-trade	22,436	22,920	19,141	85,567	73,849
(c) Changes in inventories of stock-in-trade	(94)	(169)	(59)	(11)	(335)
(d) Employee benefits expense	7,246	6,864	6,449	27,692	24,937
(e) Finance costs	1,148	1,098	1,193	4,585	4,494
(f) Depreciation and amortisation expense	2,110	1,846	1,897	7,575	6,870
(g) Other expenses	11,693	11,783	11,128	46,930	43,693
Total expenses	51,483	50,598	46,124	199,882	178,049
3 Profit/(loss) before share of profit/(loss) in associates / joint ventures and exceptional items (1) - (2)	5,050	5,309	3,596	20,061	13,606
4 Share of profit/(loss) of an associates / a joint ventures	105	53	86	330	180
5 Profit before exceptional item and tax (3) + (4)	5,155	5,362	3,682	20,391	13,786
6 Exceptional item (Refer note 3)	-	-	-	-	19
7 Profit before tax (5) + (6)	5,155	5,362	3,682	20,391	13,805
8 Tax expenses					
Current tax	1,190	1,345	887	5,263	4,368
Deferred tax	(180)	223	211	77	87
9 Profit/(Loss) for the period/year (7) - (8)	4,145	3,794	2,584	15,051	9,350
10 Other Comprehensive Income					
Items that will not be reclassified to Profit or Loss					
Remeasurement gains / (losses) on defined benefit plan	(36)	(34)	(3)	(84)	(142)
Equity instruments through other comprehensive Income	(2)			(2)	
Income tax relating to items that will not be reclassified to profit or loss	9	(1)	1	17	36
Items that will be reclassified to Profit or Loss					
Exchange differences in translating the financial statements of foreign	(1)	6	0	6	2
Total other comprehensive income/ (expense)	(30)	(29)	(2)	(63)	(104)
11 Total comprehensive income / (expense) for the period/year (after tax) (9) + (10)	4,115	3,765	2,582	14,988	9,246
Profit / (Loss) for the period attributable to:					
Owners of the parent	3,896	3,723	2,538	14,459	8,986
Non-controlling interest	249	71	46	592	364
Other comprehensive income/ (expense) for the period attributable to:					
Owners of the parent	(25)	(28)	(4)	(50)	(102)
Non-controlling interest	(5)	(1)	2	(13)	(2)
Total comprehensive income / (expense) for the period attributable to:					
Owners of the parent	3,871	3,695	2,534	14,409	8,884
Non-controlling interest	244	70	48	579	362
12 Paid-up equity share capital (Face value Rs.5/- per share)				719	719
Reserves (excluding revaluation reserves)				81,326	68,557
13 Earnings per equity share of Rs.5/- each					
Basic and Diluted EPS for the period/year (Rs.)	*27.10	*25.89	*17.65	100.56	62.50

*Not annualised

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu

Statement of Consolidated Cash Flow

(Rs. in Million)

Particulars	For the year ended March 31, 2025 Audited	For the year ended March 31, 2024 Audited
A. Cash flow from Operating Activities		
Profit for the year	15,051	9,350
Adjustments for:		
Depreciation and amortisation expense	7,575	6,870
(Profit)/loss on sale of property, plant & equipment	63	36
Profit on sale of investments (net)	(132)	(90)
Impairment in value of investment	20	-
Share of (profit)/loss of associates	(330)	(180)
Income tax expense	5,263	4,455
Finance costs	4,585	4,494
Interest income	(924)	(429)
Dividend income	(7)	-
Expected credit loss on trade receivables	629	738
Provision written back	(24)	(20)
Net gain/(loss) arising on financial assets designated as at FVTPL	(634)	(284)
Gain on fair valuation of existing interest of a joint venture pursuant to acquisition of control	-	(19)
Share-based compensation expense	1,127	875
Unrealised foreign exchange loss (net)	1	1
Operating cash flow before working capital changes	32,263	25,797
(Increase)/decrease in operating assets		
Inventories	(210)	(692)
Trade receivables	(5,642)	(3,352)
Other financial assets	315	(2,372)
Other assets	(145)	(12)
Contract assets	(263)	18
	(5,945)	(6,410)
Increase/(decrease) in operating liabilities		
Trade payables	(1,280)	4,108
Other financial liabilities	438	82
Provisions	484	332
Other liabilities	264	(40)
	(94)	4,482
Cash generated from operations	26,224	23,869
Net income tax paid	(4,860)	(4,667)
A. Net cash generated from operating activities (A)	21,364	19,202
B. Cash flow from Investing Activities		
Purchase of property, plant & equipment, CWIP & intangibles	(17,127)	(11,368)
Proceeds from sale of property, plant and equipment	149	19
Investment in bank deposits	(3,538)	(859)
Purchase of investments in subsidiary/business acquisitions	-	(37)
Proceeds from sale of non current investments	-	57
Purchase of non current investments	(7,308)	(57)
Purchase of current investments	(24,868)	(11,654)
Proceeds from sale of current investments	18,151	8,110
Loans given	(291)	(17)
Repayments received towards loans	84	41
Interest received	844	393
Dividend received	98	-
B. Net cash used in investing activities (B)	(33,806)	(15,372)
C. Cash flow from financing activities		
Proceeds from issue of equity instruments by a subsidiary company	459	25
Capital contribution from partners	10	-
Proceeds from borrowings	25,853	7,074
Transaction cost incurred on long term borrowings	(343)	-
Repayment of borrowings	(4,422)	(2,539)
Finance costs	(3,018)	(3,029)
Acquisition of additional stake in subsidiaries from non-controlling interests	(24)	(144)
Dividend paid on equity shares	(2,732)	(2,157)
Dividend paid by subsidiary to Non Controlling Interest	(52)	(52)
Payment towards lease liability	(2,563)	(2,289)
C. Net cash used in financing activities (C)	13,168	(3,111)
Net increase in cash and cash equivalents (A+B+C) = (D)	726	720
Cash and cash equivalents at the beginning of the year (E)	5,055	4,334
Add: Cash inflow due to Acquisition of controlling stake in Joint Venture	-	1
Cash and cash equivalents at the end of the year (D) +(E)	5,781	5,055
Cash and cash equivalents comprises of		
- Cash on hand	146	86
- Balance with banks	5,635	4,969
Total cash and cash equivalents at the end of the period	5,781	5,055

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
 Managing Director

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu
Consolidated Segment wise Revenue, Results, Segment Assets and Segment Liabilities

(Rs. in Million)

Particulars	Three months ended 31/03/2025	Preceding three months ended 31/12/2024	Corresponding three months ended 31/03/2024	Year to date figures for current period ended 31/03/2025	Previous year ended 31/03/2024
	Refer Note 2	Unaudited	Refer Note 2	Audited	Audited
1. Segment Revenue					
a) Healthcare services	28,431	28,029	25,795	112,201	99,392
b) Retail health & diagnostics	3,940	3,896	3,537	15,535	13,643
c) Digital health & pharmacy distribution	23,763	23,524	20,267	90,930	78,269
d) Others	12	12	12	48	47
SUB - TOTAL	56,146	55,461	49,611	218,714	191,351
Less : Intersegmental revenue	224	192	172	774	759
Income from operations	55,922	55,269	49,439	217,940	190,592
2. Segment Results					
a) Healthcare services	5,264	5,315	4,459	21,295	18,464
b) Retail health & diagnostics	118	37	68	300	(15)
c) Digital health & pharmacy distribution	230	436	(6)	1,127	(1,309)
d) Others	(25)	(19)	(13)	(79)	(103)
SUB - TOTAL	5,587	5,769	4,508	22,643	17,037
Less: (i) Finance cost	1,148	1,098	1,193	4,585	4,494
Add: (ii) Other un-allocable income, (net of expenditure)	611	638	281	2,003	1,063
Add: (iii) Exceptional item	-	-	-	-	19
Add: (iv) Share of profit/(loss) of associates / joint ventures	105	53	86	330	180
Profit Before Tax	5,155	5,362	3,682	20,391	13,805
3. Capital employed					
a) Healthcare services *					
Segment assets	127,403	124,651	114,522	127,403	114,522
Segment liabilities	(41,107)	(40,380)	(35,651)	(41,107)	(35,651)
b) Retail health & diagnostics					
Segment assets	13,277	12,537	11,574	13,277	11,574
Segment liabilities	(11,005)	(10,707)	(9,792)	(11,005)	(9,792)
c) Digital health & pharmacy distribution					
Segment assets	29,629	26,094	23,806	29,629	23,806
Segment liabilities	(10,206)	(13,485)	(12,367)	(10,206)	(12,367)
d) Others					
Segment assets	280	286	304	280	304
Segment liabilities	(179)	(177)	(188)	(179)	(188)
e) Unallocated					
Segment assets	35,984	30,449	17,325	35,984	17,325
Segment liabilities	(57,547)	(46,020)	(36,328)	(57,547)	(36,328)
Total	86,529	83,247	73,205	86,529	73,205
* Includes Capital employed in various hospital projects under construction	9,210	10,952	8,729	9,210	8,729

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
 Managing Director

Apollo Hospitals Enterprise Limited
Regd. Office: No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-Tamil Nadu

NOTES TO THE STATEMENT OF CONSOLIDATED FINANCIAL RESULTS:

1. The consolidated financial results ("the Statement") of Apollo Hospitals Enterprise Limited ("the Company") for the three months and year ended March 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on May 29, 2025 and May 30, 2025 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the consolidated financial results for the three months ended March 31, 2025 and have expressed an unmodified audit opinion on the consolidated financial results for the year ended March 31, 2025.
2. The consolidated financial results for the three months ended March 31, 2025 and March 31, 2024 are the balancing figures between the audited consolidated figures for the respective years ended on those dates and the unaudited year to date consolidated figures for the nine months ended December 31, 2024 and December 31, 2023 respectively, which were subject to limited review.
3. On August 7, 2023, Apollo Hospitals International Limited (AHIL), a subsidiary company of the Company had acquired an additional 50% stake in Amrish Oncology Services Private Ltd (AOSPL). Consequently, AOSPL became a wholly owned subsidiary of AHIL with effect from the said date. The Subsidiary Company determined a purchase price allocation based on the amounts of the identifiable assets acquired and liabilities assumed, resulting in a goodwill of Rs.274 million. The acquisition date fair value of the existing equity interest in AOSPL compared to its carrying amount resulted in a gain of Rs.19 million, which has been included under exceptional item.
4. During the year, pursuant to a proposed Scheme of Merger and Amalgamation of AOSPL into AHIL and receipt of a Confirmation Order passed by the Hon'ble Company Law Tribunal on April 25, 2025, AOSPL is merged into AHIL with an appointed date of April 01, 2024. This, being a common control transaction, has no impact on these consolidated financial results.
5. In September 2024, Apollo Healthco Limited (AHL), an unlisted material subsidiary, approved and allotted the following securities to Rasmeli Limited (an affiliate of Advent International Corporation)
 - (a) 1 (one) equity share of face value of Rs. 10/- each at a premium of Rs. 272.31 per share aggregating an amount of Rs. 282.31.
 - (b) 148,500,000 Class A fully and compulsorily convertible non-cumulative participating preference shares, (Class A CCPS) of face value of Rs. 100/- per share aggregating to Rs. 14,850 million, on the terms set out in the Investment Agreement between the Company, AHL, Rasmeli Ltd and Ms. Shobana Kamineni (promoter) as fully paid-up shares.

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

(c) 99,000,000 partly paid-up Class B fully and compulsorily convertible noncumulative participating preference shares (Class B CCPS) of face value of Rs.100/- per share aggregating to Rs. 9,900 million, on the terms set out in the Investment agreement with Rs. 25/- per share aggregating to Rs. 2,475 million to Rasmeli Limited called in the first tranche.

Further in March 2025, AHL received the balance amount of ₹7,425 million from Rasmeli Limited in relation to the subscription of Class B Compulsorily Convertible Preference Shares (CCPS), in accordance with the terms and conditions agreed under the Share Subscription Agreement.

6. During the year, AHL entered into a business transfer agreement (BTA) with Searchlight Health Private Limited to acquire the business relating to and associated with development and operation of certain Software, its licensing and associated service, for a lumpsum consideration of INR 675 million. This transaction has been accounted as asset acquisition in line with Ind AS 38 and Ind AS 103 as the fair value of the gross assets acquired is concentrated in a group or similar identifiable assets.

The consideration paid has been allocated to individual identifiable assets and liabilities on the basis of their fair values at the date of acquisition as follows:

Particulars	Rs. In million
Intangible assets under development	1,270
Property, plant and equipment	4
Cash and cash equivalents	39
Other assets	25
Borrowings	(634)
Provisions	(17)
Other liabilities	(12)
Total net identifiable assets acquired, and liabilities assumed	675

7. The Board declared an interim dividend of Rs.9.00 per share (180%) of face value of Rs.5/- each for the financial year 2024-2025. The record date for the payment was February 15, 2025 and the same was paid on February 28, 2025.
8. The Board recommended a final dividend for the year ended March 31, 2025 of Rs.10/- (200%) per equity share of face value of Rs.5/- each subject to the approval of the members at the forthcoming Annual General Meeting of the Company. The record date for the purpose of the payment of final dividend is 19th August 2025. The dividend will be paid on or before 10th September 2025.
9. CRISIL Ratings Limited has reaffirmed its rating on the Company's long term bank facilities (credit facilities) at CRISIL AA+/Stable and short term (working capital) facilities at CRISIL A1+.
10. India Ratings and Research' (Ind-Ra), a Fitch Group Company has affirmed its rating on the Company's term loans facility as 'IND AA+ indicating stable outlook.

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

11. The Honourable High Court of Karnataka on October 8, 2021 set aside the order of the Revenue Department, State of Karnataka ("Revenue Department") initiated earlier against a subsidiary alleging non-compliance of certain conditions associated with the allotment of land to the subsidiary and had directed the Revenue Department to reconsider and dispose the matter. The Revenue Department had issued a show cause notice dated February 9, 2022 seeking explanations as to why the original order needs to be withdrawn, for which the subsidiary had filed a detailed response explaining how there are no violations of the conditions relating to the allotment of the land. Based on an external legal opinion received, the subsidiary has adequate grounds to demonstrate compliance with applicable conditions and therefore is of the opinion that the matter would be settled in its favour.
12. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com).

For **APOLLO HOSPITALS ENTERPRISE LIMITED**

Place: Chennai
Date: May 30, 2025

Dr. Prathap C Reddy
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD


SUNEETA REDDY
Managing Director

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2025 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2025 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2025 of **APOLLO HOSPITALS ENTERPRISE LIMITED** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group"), and its share of the net profit after tax and other comprehensive income of its joint ventures and associates for the quarter and year ended March 31, 2025, (the "Statement"), being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements of subsidiaries, associates and joint ventures referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2025:

(i) includes the financial results of the following entities:

Name of the Company	Relationship
Apollo Hospitals Enterprise Limited (AHEL)	Parent
Apollo Home Healthcare Limited (AHHL)	Subsidiary
AB Medical Centres Limited	Subsidiary
Samudra Health Care Enterprises Limited	Subsidiary
Imperial Hospitals & Research Centre Limited	Subsidiary
Apollo Hospitals (UK) Limited	Subsidiary
Apollo Health and Lifestyle Limited (AHLL)	Subsidiary
Apollo Nellore Hospital Limited	Subsidiary
Sapien Bio-sciences Private Limited	Subsidiary
Apollo Hospitals International Limited (AHIL)	Subsidiary
Apollo Lavasa Health Corporation Limited	Subsidiary
Apollo Rajshree Hospital Private Limited (ARHPL)	Subsidiary
Future Parking Private Limited	Subsidiary
Total Health	Subsidiary
Apollo Hospitals Singapore Pte Limited	Subsidiary
Assam Hospitals Limited (Assam)	Subsidiary
Apollomedics International Lifesciences Limited	Subsidiary



N

**Deloitte
Haskins & Sells LLP**

Name of the Company	Relationship
Apollo Multi Specialty Hospitals Limited (AMSHL)	Subsidiary
Apollo HealthCo Limited (AHL)	Subsidiary
Apollo Hospitals North Limited	Subsidiary
Kerala First Health Services Private Limited (KFHS)	Subsidiary
Health Axis Private Limited (HAPL)	Subsidiary
Apollo Hospitals Jammu and Kashmir Limited	Subsidiary
Apollo Hospitals Worli LLP (w.e.f. 12 July 2024)	Subsidiary
Alliance Dental Care Limited	Subsidiary of AHLL
Apollo Dialysis Private Limited	Subsidiary of AHLL
Apollo Sugar Clinics Limited	Subsidiary of AHLL
Apollo Speciality Hospitals Limited	Subsidiary of AHLL
AHLL Diagnostics Limited	Subsidiary of AHLL
AHLL Risk Management Private Limited	Subsidiary of AHLL
Care Diagnostics Private Limited (w.e.f. 1 February 2025)	Subsidiary of AHLL
Sobhagya Hospital and Research Centre Private Limited	Subsidiary of ARHPL
Apollo Fertility Centre Private Limited (Formerly known as Surya Fertility Centre Private Limited)	Stepdown Subsidiary of AHLL
Apollo Spectra Centres Private Limited (Formerly known as Kshema Healthcare Private Limited)	Stepdown Subsidiary of AHLL
Apollo Cradle and Children Hospital Private Limited	Stepdown Subsidiary of AHLL
Apollo 24/7 Insurance Services Limited (w.e.f. 3 September 2024)	Subsidiary of AHL
Asclepius Hospitals and Healthcare Private Limited	Subsidiary of Assam
Apollo CVHF Limited	Subsidiary of AHIL
Baalayam Healthcare Private Limited	Subsidiary of KFHS
Family Health Plan Insurance (TPA) Limited	Associate
Indraprastha Medical Corporation Limited	Associate
Stemcyte India Therapeutics Private Limited	Associate
Apollo Medical Private Limited (AMPL)	Associate of AHL
Apollo Pharmacies Limited	Subsidiary of AMPL
Apollo Pharmalogistics Private Limited	Subsidiary of AMPL
Apollo Gleneagles PET-CT Private Limited	Joint venture
ApoKos Rehab Private Limited	Joint venture
Nexify Health Private Limited (w.e.f. 30 September 2024)	Joint venture of HAPL



M

Deloitte Haskins & Sells LLP

- (ii) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the year ended March 31, 2025.

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2025

With respect to the Consolidated Financial Results for the quarter ended March 31, 2025, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review reports of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group, its associates and joint ventures in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Emphasis of Matter

We draw attention to Note 11 of the Consolidated financial results in respect of proceedings initiated against the company's subsidiary, Imperial Hospital and Research Centre Limited, by the Government of Karnataka.

Our report is not modified in respect of this matter.



Management's and Board of Directors' Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2025, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2025 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including its associates and joint ventures in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

The respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its associates and joint ventures and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for overseeing the financial reporting process of the Group and of its associates and joint ventures.

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.



(1)

Deloitte Haskins & Sells LLP

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and joint ventures to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and joint ventures to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the entities within the Group and its associates and joint ventures to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.



M

Deloitte Haskins & Sells LLP

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2025

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.

We did not audit the financial statements of 30 subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs. 31,027 million as at March 31, 2025 and total revenues of Rs. 4,408 million and Rs. 17,384 million for the quarter and year ended March 31, 2025 respectively, total net profit after tax of Rs. 501 million and Rs. 1,247 million for the quarter and year ended March 31, 2025 respectively and total comprehensive income (net) of Rs. 486 million and Rs. 1,212 for the quarter and year ended March 31, 2025 respectively and net cash flows of Rs. 561 million for the year ended March 31, 2025, as considered in the Statement. The consolidated financial results also includes the Group's share of total net profit after tax of Rs. 106 million and Rs. 330 million for the quarter and year ended March 31, 2025 respectively and total comprehensive income (net) of Rs. 100 million and Rs. 327 million for the quarter and year ended March 31, 2025 respectively, as considered in the Statement, in respect of 6 associates (including 2 subsidiaries of 1 associate) and 2 joint ventures whose financial statements have not been audited by us. These financial statements have been audited, as applicable, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.



M

**Deloitte
Haskins & Sells LLP**

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

- The consolidated financial results includes the unaudited financial statements of 1 subsidiary whose financial statements reflect total assets of Rs. 0.53 million as at March 31, 2025 and total revenues of Rs. Nil and Rs. Nil for the quarter and year ended March 31, 2025 respectively, total net (loss) after tax of Rs. 0.18 million and Rs. 0.18 million for the quarter and year ended March 31, 2025 respectively and total comprehensive loss of Rs. 0.85 million and Rs. 0.85 million for the quarter and year ended March 31, 2025 respectively and net cash flows of Rs. Nil for the year ended March 31, 2025 as considered in the Statement. These financial statements are unaudited and have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial statements are not material to the Group.

Our report on the Statement is not modified in respect of the above matter with respect to our reliance on the financial information certified by the Board of the Directors.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)




Nachiappan Subramanian
Partner
(Membership No. 218727)
(UDIN: 25218727BMOEIR1856)

Place: Chennai
Date: May 30, 2025

30th May 2025

Apollo Hospitals announces Q4FY25 & FY25 results

FY25 Consolidated Revenue crosses Rs. 20,000 Crores milestone
FY25 Healthcare Services Revenue crosses Rs. 10,000 Crores milestone

Q4 FY25 Consolidated Revenues grew 13% YoY to Rs. 5,592 Crores
FY25 Consolidated Revenues rose 14% YoY to Rs. 21,794 Crores

Q4 FY25 Consolidated EBITDA increased 20% YoY to Rs. 770 Crores
FY25 Consolidated EBITDA increased 26% YoY to Rs. 3,022 Crores

Q4 FY25 Consolidated PAT at Rs. 390 Crores, 54% YoY Growth
FY25 Consolidated PAT at Rs. 1,446 Crores, 61% YoY Growth

Final Dividend of Rs. 10 per share, making for a Total Dividend of Rs. 19 per share, on face value of Rs. 5 per share.

Announces significant expansion in the Sarjapur micro-market through the addition of 700 beds in 2 stages, to establish a dominant presence in the south-eastern part of Bengaluru with wide addressable market.

Stage 1: Acquisition of an existing 200 bedded hospital (leased facility).

Stage 2: Establishing a 500-bed greenfield hospital in close proximity

With the ongoing brownfield expansions in the city, the total bed strength in Bengaluru will be ~ 1,500 beds.

Brownfield expansion in Hyderabad by 160 beds through brownfield expansion at the existing Jubilee Hills and Secunderabad facilities.

Along with the upcoming facility in Gachibowli, Apollo Hospitals bed strength in Hyderabad will be ~1,400 beds.

With these announcements, Apollo Hospitals commits to adding over 4,300 beds over a period of 3 to 4 years, beginning FY26 with a total capital outlay of over Rs. 8,000 crores, with a balance capital outlay of over Rs. 6,000 crs.

Apollo Hospitals crossed the landmark milestone of 25,000 transplants across its network, reaffirming its leadership in complex, high-acuity care.

Dr. Prathap C Reddy, Chairman, Apollo Hospitals Enterprise Ltd. said: *"At Apollo, our mission has always gone beyond treating illness—it is about enabling every individual to live a healthier, happier life. FY25 was a defining year. With revenues crossing ₹20,000 crores and Healthcare Services surpassing ₹11,000 crores, we are humbled by the trust placed in us across India and beyond.*

Technology expanded the possibilities of healing, but compassion remained our foundation. A strong rise in patient volumes is a testament to the deep confidence people have in Apollo's care and our differentiated Centers of Excellence. As we grow, our focus remains unwavering—making advanced, high-quality care accessible and affordable to all.

To address the rising burden of non-communicable diseases, we are intensifying our preventive care mission. Through Apollo ProHealth, we are set to globally launch pioneering wellness programs that redefine the healthcare landscape — shifting the focus from reactive treatment to proactive, preventive care.

Innovation remains our most powerful ally — from AI-powered diagnostics to precision robotic surgeries, all enabled by a digital backbone that is reimagining the entire patient-care journey, enabling care that is predictive, personalised, and scalable.

*We are committed to growth and to the enhancement of our care touchpoints, with new hospitals to be commissioned this year in Pune, Kolkata, Hyderabad, Bangalore and Delhi NCR — and several more in varying stages of development. These state-of-the-art facilities will be equipped with cutting-edge medical technology, reinforcing our commitment to delivering world-class care at scale. **Our over ₹8,000 crore investment over the next five years will add over 4,300 beds, with the first phase of ~ 2,000 beds already in progress—bringing advanced care closer to communities across India.***

We are heartened by the performance of Apollo HealthCo and AHLL, two strong pillars of the integrated care network we have created for the consumer. Apollo Pharmacies crossed 6,600 stores this year and Apollo 24/7 commenced distribution of Insurance products to increase access to care. AHLL has strengthened its capability through its Global Reference Labs and highly specialized test menu updated for the latest medical advancements.

But what truly drives Apollo forward is our people—the doctors, nurses, and caregivers who carry our legacy in every life they touch. Their commitment is creating a healthcare system that is not only clinically world-class but also deeply human.

As we step into FY26, our purpose remains clear: to touch a billion lives, lead with innovation and empathy, and help build a healthier, stronger India for future generations."

Q4FY25 CONSOLIDATED RESULTS

REVENUE

Q4FY25 Revenues grew 13% YoY to Rs. 5,592 Crores;

- Healthcare Services (HCS) Revenue at Rs. 2,822 Crores; 10% YoY growth
- AHLL Revenues at Rs. 394 Crores; 11% YoY growth
- Apollo HealthCo Revenues at Rs. 2,376 Crores; 17% YoY growth
- GMV of Apollo 24/7 at Rs. 795 Crores

EBITDA

Q4FY25 Consolidated EBITDA grew 20% YoY to Rs. 770 Crores;

- Healthcare Services (HCS) EBITDA at Rs. 686 Crores; 16% YoY growth
- AHLL EBITDA at Rs. 47 Crores; 32% YoY growth
- Apollo HealthCo EBITDA at Rs. 36 Crores

PAT

Q4FY25 Consolidated PAT grew 54% YoY to Rs. 390 Crores;

- Healthcare Services (HCS) PAT at Rs. 385 Crore; 37% YoY growth
- AHLL PAT loss of Rs. 4 Crores
- Apollo HealthCo PAT at Rs. 9 Crores

FY25 CONSOLIDATED RESULTS

REVENUE

FY25 Revenues grew 14% YoY to Rs. 21,794 Crores;

- Healthcare Services (HCS) Revenue at Rs. 11,147 Crores; 13% YoY growth
- AHLL Revenues at Rs. 1,554 Crores; 14% YoY growth
- Apollo HealthCo Revenues at Rs. 9,093 Crores; 16% YoY growth
- GMV of Apollo 24/7 at Rs. 3,007 Crores

EBITDA

FY25 Consolidated EBITDA grew 26% YoY to Rs. 3,022 Crores;

- Healthcare Services (HCS) EBITDA at Rs. 2,701 Crores; 15% YoY growth
- AHLL EBITDA at Rs. 154 Crores; 32% YoY growth
- Apollo HealthCo EBITDA at Rs. 168 Crores

PAT

FY25 Consolidated PAT grew 61% YoY to Rs. 1,446 Crores;

- Healthcare Services (HCS) PAT at Rs. 1,426 Crores; 25% YoY growth
- AHLL PAT loss of Rs. 27 Crores
- Apollo HealthCo PAT at Rs. 47 Crores

Financial Performance – Q4FY25

Consolidated Q4FY25 Performance

- Revenues at Rs. 55,923 mn vs Rs.49,439 mn in Q4 FY24; 13% YoY growth
- EBITDA grew by 20% at Rs. 7,699 mn vs Rs.6,405 mn in Q4 FY24. This is after Apollo 24/7 cost of Rs. 1,603 mn in the quarter (incl. Rs. 455 mn non-cash ESOP charge) vs Rs 1,508 mn in Q4 FY24.
- Reported PAT at Rs. 3,897 mn vs Rs.2,538 mn in Q4 FY24; 54% YoY growth
- Diluted EPS of Rs. 27.10 per share in Q4 FY25 (not annualized)

Healthcare service Q4FY25 Performance

- Revenue at Rs. 28,220 mn vs Rs. 25,626 mn in Q4 FY24; 10% YoY growth
- EBITDA grew by 16% at Rs. 6,863 mn vs Rs. 5,931 mn in Q4 FY24; Margins at 24.3% in Q4 FY25
- PAT stood at Rs. 3,852 mn vs Rs. 2,803 mn in Q4 FY24, 37% YoY growth

Apollo Health and Lifestyle Limited Q4FY25 Performance

- Revenue at Rs. 3,940 mn vs Rs. 3,547 mn in Q4 FY24; 11% YoY growth
- EBITDA grew by 32% at Rs. 472 mn vs Rs. 357 mn in Q4 FY24; Margins at 12.0% in Q4 FY25
- PAT loss of Rs. 43 mn vs loss of Rs. 87 mn in Q4 FY24

Apollo HealthCo Q4FY25 Performance

- Revenue at Rs. 23,763 mn vs Rs. 20,267 mn in Q4 FY24; 17% YoY growth
- EBITDA at Rs. 363 mn vs Rs. 117 mn in Q4 FY24; Margins at 1.5 % in Q4 FY25
- PAT stood at Rs. 88 mn vs loss of Rs. 177 mn in Q4 FY24

Financial Performance – FY25

Consolidated FY25 Performance

- Revenues at Rs. 217,940 mn vs Rs. 190,592 mn in FY24; 14% YoY growth
- EBITDA grew by 26% at Rs. 30,219 mn vs Rs. 23,907 mn in FY24. This is after Apollo 24/7 cost of Rs. 5,857 mn in FY25 (incl. Rs. 1,076 mn non-cash ESOP charge) vs Rs. 7,077 mn in FY24.
- Reported PAT at Rs. 14,460 mn vs Rs.8,986 mn in FY24; 61% YoY growth
- Diluted EPS of Rs. 100.56 per share in FY25

Healthcare service FY25 Performance

- Revenue at Rs. 111,475 mn vs Rs. 98,670 mn in FY24; 13% YoY growth
- EBITDA grew by 15% at Rs. 27,005 mn vs Rs. 23,558 mn in FY24; Margins at 24.2% in FY25
- PAT stood at Rs. 14,261 mn vs Rs. 11,450 mn in FY24, 25% YoY growth

Apollo Health and Lifestyle Limited FY25 Performance

- Revenue at Rs. 15,535 mn vs Rs. 13,653 mn in FY24; 14% YoY growth
- EBITDA grew by 32% at Rs. 1,538 mn vs Rs. 1,166 mn in FY24; Margins at 9.9% in FY25
- PAT loss of Rs. 270 mn vs loss of Rs. 508 mn in FY24

Apollo HealthCo FY25 Performance

- Revenue at Rs. 90,930 mn vs Rs. 78,269 mn in FY24; 16% YoY growth
- EBITDA at Rs. 1,676 mn vs loss of Rs. 817 mn in FY24; Margins at 1.8% in FY25
- PAT stood at Rs. 469 mn vs loss of Rs. 1,957 mn in FY24

Q4FY25 Segment-wise Performance Update

Healthcare Services (Hospitals)

As on March 31, 2025, Apollo Hospitals had 8,025 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 67% vs 65% in the same period in the previous year. IP volumes grew 4% in Q4 FY25 – and is the penultimate quarter which bears the base impact of Bangladesh patients, given the drop-off resulting from the change in Bangladesh government and pursuant change in visa application and norms.

Consolidated Revenues of the healthcare services division grew by 10% to Rs. 28,220 million in Q4 FY25 compared to Rs.25,626 million in Q4 FY24.

EBITDA (Post Ind AS 116) was at Rs. 6,863 million in Q4 FY25 compared to Rs. 5,931 million in Q4 FY24. EBITDA grew 16% YoY.

Revenues in the Tamil Nadu cluster grew by 7%, IP Volumes grew by 1%. ARPOB grew by 4% to Rs. 78,133. Overall occupancy in the cluster was 1337 beds (65% occupancy) as compared to 1,288 beds (63% occupancy) in the previous year.

In AP Telangana region, Revenues grew by 19%, IP volumes grew by 10%. ARPOB grew by 8% to Rs. 65,572. Occupancy in the cluster was 788 beds (64% occupancy) as compared to 712 beds (56% occupancy) in the previous year.

In Karnataka region, Revenues grew by 15%, IP volumes grew by 2%. ARPOB grew by 10% to Rs. 70,598. Occupancy in the cluster was 538 beds (70% occupancy) as compared to 512 beds (68% occupancy) in the previous year.

In Eastern region, Revenues grew by 8%, IP volumes grew by 4%. ARPOB grew by 7% to Rs. 48,462. Occupancy in the cluster was 1,367 beds (73% occupancy) as compared to 1,347 beds (74% occupancy) in the previous year.

In Western region, Revenues grew by 14%, IP volumes grew by 6%. ARPOB grew by 15% to Rs. 56,053. Occupancy in the cluster was 491 beds (56% occupancy) as compared to 492 beds (57% occupancy) in the previous year.

In Northern region, Revenues grew by 9%, IP volumes grew by 6%. ARPOB grew by 4% to Rs. 64,191. Occupancy in the cluster was 844 beds (70% occupancy) as compared to 801 beds (66% occupancy) in the previous year.

The strong performance in Karnataka and AP Telangana region, is testament of the Apollo brand resilience, and the consumers trust in Apollo as care-provider of choice in the regions. Apollo Hospitals' plans to increase penetration in Bangalore and Hyderabad through a mix of Brownfield and Greenfield projects.

Hyderabad: Apollo Hospitals has approved the brownfield expansion of 160 beds spread across the Jubilee Hills and Secunderabad facilities, which should become operational in the coming 3-4 years.

Bengaluru: Apollo Hospitals has acquired an existing 200-bed hospital in Sarjapur, which should come into the fold in the next 2 quarters augmenting the current care network and expanding the coverage in the city. This foray into Sarjapur would improve access for consumers in South-east Bengaluru, which is home to many technocrats and large IT businesses. Apollo Hospitals' has also acquired a 2.53 acre land in Sarjapur for a 500 bed Greenfield Hospital, which is expected to become operational in 3-4 years.

Apollo Health and Lifestyle Limited: Diagnostics and Retail Healthcare

- AHLL Gross Revenue at Rs. 3,940 million; 11% YoY growth
- Diagnostics Revenue stood at Rs. 1,278 million and Spectra at Rs. 701 million

Apollo HealthCo: Digital Healthcare and Omni-channel Pharmacy platform

- Offline Pharmacy distribution revenues at Rs. 20,844 million in Q4 FY25 while Revenues from Digital platform were at Rs. 2,919 million
- Overall Health Co Revenues were at Rs. 23,763 million representing 17% YoY growth.
- 266 net new stores were opened in this quarter, taking the total number to 6,626 stores.
- GMV of Apollo 24/7 at Rs. 7,954 million in Q4 FY25, growth of 11% over Q4 FY24.
- Avg Q4 FY25 run rate of 83K/day order across Pharma, Diagnostics Consultations (including IP/OP referrals) compared to 58K/day in Q4 FY24.

CLINICAL EXCELLENCE HIGHLIGHTS

- Apollo Hospitals crossed the milestone of 25,000+ cumulative transplants, with Hyderabad playing a pivotal role—reaffirming Apollo’s leadership in complex, high-acuity care and transplant innovation.
- Apollo Children’s Hospital, Chennai successfully performed a left thoracoscopic upper lobectomy on a 9-month-old infant with congenital pulmonary airway malformation—demonstrating advanced pediatric surgical capabilities using minimally invasive techniques.
- Indraprastha Apollo Hospitals, Delhi performed a landmark double lung transplant on a 42-year-old male patient with end-stage interstitial lung disease, along with rare complex limb salvage surgeries and aggressive cancer reconstructions for international patients.
- Apollo Hospitals, Navi Mumbai conducted Maharashtra’s first Robotic Nipple-Sparing Mastectomy with TiLoop reconstruction on a BRCA-positive patient, and completed 78 bone marrow transplants while launching a new 12-bed Advanced Liver ICU.
- Apollo Cancer Institute, Teynampet performed a novel hemi-circumferential portal vein resection to treat advanced pancreatic cancer, preserving splenic vein drainage and avoiding secondary interventions.
- Apollo Hospitals, Hyderabad launched an innovative Joint Preservation Program and became the first in the network to complete 25 Fast-track Deep Brain Stimulation surgeries in a 24-day period, and pioneered the use of an atrial flow regulator implant in a pediatric pulmonary hypertension case.
- Apollo Hospitals, Bangalore performed a mitral valve edge-to-edge repair using the MitraClip, reinforcing its expertise in structural heart procedures.
- Apollo Hospitals, Madurai successfully treated a rare condition called hematohidrosis in a 20-year-old female patient.
- Apollo Hospitals, Mysore resected a rare acral fibromyxoma tumour from the palm of a 58-year-old male patient using a complex surgical procedure with full sensorimotor preservation.
- Apollo Hospitals, Kolkata carried out a robot-assisted choledochal cyst surgery for a two-year-old child, marking a milestone in pediatric robotic surgery in the region.

NEW LAUNCHES, INITIATIVES AND PARTNERSHIPS

- Apollo Hospitals launched the Centre for Digital Health and Precision Medicine in collaboration with the University of Leicester, UK—focusing on AI-integrated diagnostics, genomics, and precision-led care transformation.
- A strategic Memorandum of Understanding (MoU) was signed with Mayapada Healthcare, Indonesia, to strengthen cross-border medical collaboration and clinical knowledge exchange across Southeast Asia.
- Apollo Hospitals, Navi Mumbai launched a dedicated 12-bed Advanced Liver ICU, supporting complex hepatology cases with state-of-the-art critical care infrastructure.
- Apollo Hospitals, Bangalore introduced 'Seniors First', a proactive geriatric care initiative that delivers personalized, preventive healthcare for India's ageing population.
- Apollo Hospitals, Hyderabad initiated a new Joint Preservation Program, offering early intervention through multidisciplinary, non-surgical therapies to delay or prevent joint replacements.
- Apollo Hospitals rolled out 'The Pink Book', a comprehensive institutional framework to safeguard healthcare workers and promote a robust culture of safety, trust, and accountability across the hospital network.

AWARDS AND ACCOLADES

- Apollo Hospitals received 15 prestigious awards in Q4 FY25, reflecting its excellence in clinical care, green infrastructure, patient trust, and community engagement.
- Apollo Hospitals, Navi Mumbai emerged as a standout, receiving five major recognitions:
 - Big FM's Big Impact Creator Award (Super Speciality Hospitals, 2025)
 - Sakal Sanman Award
 - Best Super Speciality Hospital in Mumbai by the Navabharath Group
 - Leading Quaternary Care Hospital by the Times Group
 - IGBC Platinum Certification for excellence in green building standards, by the Indian Green Building Council
- Apollo Hospitals, Ahmedabad was honoured at the FICCI Medical Value Travel Awards for its role in attracting international patients and promoting India as a hub for high-quality, affordable care.

- In the Northeast, Apollo Hospitals, Guwahati was named Hospital of the Year by News18, and its affiliate Excelcare earned four recognitions:
 - Stroke Readiness (News18 Assam)
 - Best Practices in CSSD (CAHO)
 - Excellence in Infection Control (AHPI, Association of Hospital Providers (India))
 - Best Community Outreach Program (Ankuram)

- Apollo Hospitals, Hyderabad received two prestigious recognitions:
 - Certificate of Recognition from the Association of Healthcare Providers (India)
 - Stroke Center Certification from the American Heart Association

- Apollo Hospitals, Chennai was ranked among the World's Best Hospitals 2025 by Newsweek and named the Most Trusted Hospital by the Times Health Excellence Awards.

- Apollo Hospitals, Karnataka was honoured at the FICCI Women's Achievers Awards, recognising the institution's commitment to diversity, inclusion, and clinical excellence.

About Apollo

Apollo revolutionized healthcare when Dr. Prathap Reddy opened the first hospital in Chennai in 1983. Today, Apollo is the world's largest integrated healthcare platform with over 10,000 beds across 73 hospitals, 6,600+ pharmacies, 260+ clinics, 2,200+ diagnostic centres, and 800+ telemedicine centres. It is one of the world's leading cardiac centers, having performed over 3,00,000 angioplasties and 2,00,000 surgeries. Apollo continues to invest in research and innovation to bring the most cutting-edge technologies, equipment, and treatment protocols to ensure patients have access to the best care in the world. Apollo's 1,20,000 family members are dedicated to delivering exceptional care and leaving the world better than we found it.

For further details, log onto: www.apollohospitals.com

For further information, please contact:

For Media / Investors

R Krishnakumar
Apollo Hospitals Ltd.
Krishnakumar_r@apollohospitals.com
+91 44 2829 7840

Mayank Vaswani
CDR India
mayank@cdr-india.com
+91 22 6645 1230

Disclaimer

Some of the statements in this document that are not historical facts are forward looking statements. These forward looking statements include our financial and growth projections as well as statements concerning our plans, strategies, intentions and beliefs concerning our business and the markets in which we operate.

These statements are based on information currently available to us, and we assume no obligation to update these statements as circumstances change. There are risks and uncertainties that could cause actual events to differ materially from these forward-looking statements. These risks include, but are not limited to, the level of market demand for our services, the highly-competitive market for the types of services that we offer, market conditions that could cause our customers to reduce their spending for our services, our ability to create, acquire and build new businesses and to grow our existing businesses, our ability to attract and retain qualified personnel, currency fluctuations and market conditions in India and elsewhere around the world, and other risks not specifically mentioned herein but those that are common to industry.

Further, this document may make references to reports and publications available in the public domain. Apollo Hospitals Enterprise Ltd. makes no representation as to their accuracy or that the company subscribes to those views / findings.

Annexure - 2

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Particulars	Details
Reason for change viz., appointment, resignation, removal or otherwise	Appointment of Lakshmmi Subramanian & Associates, Peer Reviewed Firm of Company Secretaries in Practice (Firm registration number: P2024TN103000), as Secretarial Auditors of the Company.
Date of Appointment/ cessation	The Board at its meeting held on May 30, 2025, approved the appointment of Lakshmmi Subramanian & Associates as Secretarial Auditors, for audit period of five consecutive years commencing from FY 2025-26 till FY 2029-2030, subject to approval of the shareholders.
Brief Profile (in case of appointment)	<p>Lakshmmi Subramanian & Associates (LSA) is a peer reviewed and distinguished firm of Practicing Company Secretaries, with an enduring legacy of over three decades in the domain of corporate legal advisory.</p> <p>LSA has, for more than 37 years, consistently served as a trusted counsel to a diverse clientele—including large listed corporations, multinational entities, and prominent domestic companies—providing strategic and legally sound advice on critical business matters.</p> <p>The firm is led by experienced partners, all of whom are distinguished professionals in the field of corporate law and compliance</p>
Relationship (in case of appointment)	Not applicable




Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Particulars	Ms. Preetha Reddy	Ms.Suneeta Reddy	Ms.Sangita Reddy
Reason for change viz., appointment, resignation, removal or otherwise	<p>The existing term of Ms. Preetha Reddy as whole time director designated as Executive Vice Chairperson is due for renewal on 2nd February 2026.</p> <p>Based on the recommendations of the Nomination and Remuneration Committee, the Board approved the re-appointment of Ms. Preetha Reddy as whole time director as Executive Vice Chairperson of the Company for a further period of five years w.e.f. 3rd February 2026 and recommended for the member's approval.</p>	<p>The existing term of Ms. Suneeta Reddy as Managing Director is due for renewal on 2nd February 2026.</p> <p>Based on the recommendations of the Nomination and Remuneration Committee, the Board approved the re-appointment of Ms. Suneeta Reddy as Managing Director of the Company for a further period of five years w.e.f. 3rd February 2026 and recommended for the member's approval.</p>	<p>The existing term of Ms. Sangita Reddy as Joint Managing Director is due for renewal on 2nd February 2026.</p> <p>Based on the recommendations of the Nomination and Remuneration Committee, the Board approved the re-appointment of Ms. Sangita Reddy as Joint Managing Director of the Company for a further period of five years w.e.f. 3rd February 2026 and recommended for the member's approval.</p>
Date of Appointment/cessation & term of appointment	Ms.Preetha Reddy has been reappointed as Executive Vice Chairperson of the Company for a further period of five years w.e.f. 3 rd February 2026 subject to members approval in the ensuing annual general meeting.	Ms.Suneeta Reddy has been reappointed as Managing Director of the Company for a further period of five years w.e.f. 3 rd February 2026 subject to members approval in the ensuing annual general meeting.	Ms.Sangita Reddy has been reappointed as Joint Managing Director of the Company for a further period of five years w.e.f. 3 rd February 2026 subject to members approval in the ensuing annual general meeting.




Particulars	Ms. Preetha Reddy	Ms.Suneeta Reddy	Ms.Sangita Reddy
Brief Profile (in case of appointment)	Annexure Enclosed	Annexure Enclosed	Annexure Enclosed
Relationship (in case of appointment)	Ms. Preetha Reddy is daughter of Dr. Prathap C Reddy, Executive Chairman and sister of Smt. Suneeta Reddy, Managing Director, Smt. Shobana Kamineni, Non-Executive Director and Smt. Sangita Reddy, Joint Managing Director.	Ms. Suneeta Reddy is daughter of Dr. Prathap C Reddy, Executive Chairman and sister of Smt. Preetha Reddy, Executive Vice Chairperson, Smt. Shobana Kamineni, Non-Executive Director and Smt. Sangita Reddy, Joint Managing Director.	Ms. Sangita Reddy is daughter of Dr. Prathap C Reddy, Executive Chairman and sister of Smt. Preetha Reddy, Executive Vice Chairperson, Smt. Suneeta Reddy, Managing Director and Smt. Shobana Kamineni, Non-Executive Director.
Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018 /02 dated June 20, 2018 issued by the BSE and NSE, respectively	Ms. Preetha Reddy is not debarred from holding office of a Director by virtue of any SEBI Order or any other such authority.	Ms. Suneeta Reddy is not debarred from holding office of a Director by virtue of any SEBI Order or any other such authority.	Ms. Sangita Reddy is not debarred from holding office of a Director by virtue of any SEBI Order or any other such authority.




Annexure-4

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Particulars	Mr. Som Mittal
Reason for change viz., appointment, resignation, removal or otherwise	<p>Mr. Som Mittal current tenure (1st term) as an Independent Director of the Company expires on July 20, 2026.</p> <p>Based on the recommendation of the Nomination and Remuneration Committee of the Company, the Board of Directors at its meeting held today i.e., May 30, 2025 has approved the re-appointment of Mr. Som Mittal, as an Independent Director for a second term of five consecutive years from July 21, 2026 to July 20, 2031, subject to the approval of the members at the general meeting</p>
Date of Appointment/ cessation & term of appointment	<p>Re-appointment with effect from July 21, 2026. Five years i.e., w.e.f. July 21, 2026 to July 20, 2031, subject to the approval of shareholders</p>
Brief Profile (in case of appointment)	Annexure Enclosed
Relationship (in case of appointment)	Mr. Som Mittal is not related to any Directors or Key Managerial Personnel of the Company.
Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018 /02 dated June 20, 2018 issued by the BSE and NSE, respectively	Mr. Som Mittal is not debarred from holding office of a Director by virtue of any SEBI Order or any other such authority.




Profiles

Ms. Preetha Reddy

Ms. Preetha Reddy holds a Bachelor's degree in Science and a Masters' in Public Administration. She was conferred the degree of Doctor of Science (Honoris Causa) by The Tamil Nadu Dr. MGR Medical University in recognition of her outstanding work in the field of healthcare.

As Vice Chairperson of Apollo Hospitals, Ms. Preetha Reddy has been instrumental in championing clinical excellence, deep clinician engagement, and the implementation of modern medical protocols across the organization. Her efforts have significantly contributed to Apollo achieving clinical outcomes that often surpass international benchmarks.

A strong advocate for medical innovation, she has led the adoption of advanced technologies such as South Asia's first Proton Cancer Therapy and the Zap-X, helping bridge the gap in access to cutting-edge treatments. Under her leadership, Apollo has built a robust clinical team of over 12,000 professionals and established platforms that enable the delivery of world-class healthcare.

Ms. Preetha Reddy also led the establishment of the Cell & Molecular Biology Research Centre (CMBRC) in Hyderabad and the Apollo Research Academy, fostering a research-driven culture focused on clinical innovation, precision medicine, and ethical standards. These institutions consolidate Apollo's research efforts and drive global healthcare innovation in collaboration with international partners.

She played a pivotal role in achieving India's first JCI accreditation for a hospital and was instrumental in developing the NABH accreditation framework, thereby uplifting quality standards across Indian hospitals. Currently, she serves on the Steering Committee for grading NABH Accredited Healthcare Organizations and is a member of the Advisory Board of the Ethical Principles in Health Care (EPIHC), an initiative of the IFC and World Bank. In 2024, she joined the High-Level Advisory Council on Jobs, a World Bank initiative aimed at addressing the global employment crisis.

Her commitment extends beyond healthcare delivery to social impact. She has championed community health through initiatives like SACHi and the Total Health Foundation, and has played a key role in disaster relief and rehabilitation efforts across the country.

Awards and Recognitions

Over the years, Ms. Preetha Reddy has been widely recognized for her leadership:

- 2024: Named among the 100 Most Powerful Women in Asia by Fortune Asia; received the Woman Business Leader award at Moneycontrol's Indian Family Business Awards
- 2023: Awarded the Sir Jehangir Ghandy Medal for Industrial and Social Peace by XLRI-Xavier School of Management
- 2021: Honored with the Economic Times Businesswoman of the Year Award and Healthcare Personality of the Year by FICCI for Apollo's contributions during the COVID-19 pandemic
- 2018: Received the ABLF Award for Business Courage from the Asian Business Leaders Forum
- Additionally recognized with the Lifetime Achievement Award by the Loyola Forum for Historical Research, the Devi Award from The New Indian Express Group, and the NHRDN People CEO Award – Women Leadership



Ms.Suneeta Reddy

Ms Suneeta Reddy holds a Bachelor of Arts degree from Stella Maris College, Chennai, and a Diploma in Financial Management from the Institute of Financial Management and Research, Chennai. She is also an alumna of the Owner/President Management Program at Harvard Business School, Boston, USA, and holds an honorary doctorate in Business Management from XIMB Bhubaneswar.

Under her guidance, Apollo Hospitals has set benchmarks in clinical excellence, adopting cutting-edge protocols and fostering innovation. Her leadership in clinical quality and innovation is evident in her role as a mentor to the Apollo Clinical Innovation Group, driving the implementation of novel clinical practices.

Ms. Suneeta Reddy's influence extends beyond Apollo, as evidenced by her significant contributions to various boards and councils. Her roles as a past President of the India International Chamber of Commerce and President of the All-India Management Association underline her commitment to advancing healthcare and management practices.

Furthermore, her active participation in the Confederation of Indian Industry and her directorship at the Chennai International Centre and on Harvard Business School's advisory boards reflect her broad impact on the global business and healthcare landscapes.

Awards and Recognitions

Her exceptional leadership and contributions to healthcare and business have garnered widespread recognition. Smt. Reddy has been featured among the top ten in Fortune India's Most Powerful Women list for five consecutive years from 2018 to 2023—an accolade that celebrates influential women leaders. She has also been honoured with the Most Powerful Women in Indian Business Award by Business Today in 2019 and 2022, the Economic Times Awards for Corporate Excellence as Businesswoman of the Year in 2020, and the Best CEO Award from Business Today in 2023.

Most recently, in 2024, she was recognized among the 50 CNBC Global Changemakers: Women Transforming Business, highlighting her transformative impact on the global business world.



Ms.Sangita Reddy

Ms. Sangita Reddy holds a graduate degree in Science from Women's Christian College, Chennai, and has pursued post-graduate studies in Hospital Administration at renowned institutions including Rutgers University, Harvard University, and the National University of Singapore. In recognition of her outstanding contributions to healthcare and society, she has been conferred Honorary Doctorates by esteemed institutions such as Macquarie University, Australia, and Amity University, India.

Ms. Sangita Reddy has been actively engaged in collaboration with governments and industry bodies on a spectrum of public health and policy development matters. She was appointed to the CSIR overarching committee, where she works in close proximity to the Indian scientific and research community in order to hasten the application of science for the benefit of the nation in various ways, ranging from economic prosperity to social wellbeing and healthcare.

Ms. Reddy has been successful in advocating and promulgating policy reforms, and her insights have been sought after on various international healthcare forums, including the World Health Congress. Additionally, as a member of the Rockefeller Working Group, she has contributed significantly to the advancement of the private sector's role in the global healthcare industry.

Committed to the establishment of a more comprehensive public and private healthcare system in the nation, one of Ms. Sangita Reddy's initiatives has been Apollo Clinics, which aspires to create a series of tech-driven primary care clinics throughout urban and rural India.

Recently appointed to the Board of Joint Commission Resources, Inc. (JCR), a knowledgeable resource for healthcare organizations, Smt. Reddy will impart her global competencies and guidance to enhance the safety and excellence of healthcare in the United States and other countries.

In India's G20 Presidency, she was appointed Chairperson of G20 Empower India and was the former President of the Federation of Indian Chambers of Commerce and Industry (FICCI). Additionally, she is the Chairperson of the BRICS Women's Business Alliance, India.

Awards and Recognitions

Smt. Sangita Reddy has received numerous awards, including:

- CNN-News18 Indian of the Year 2024 for Business Excellence, recognizing her luminous leadership and ground-breaking vision in the healthcare sector.
- Women in Excellence Healthcare Award 2022 by FICCI's The Greater50 Initiative.
- Best Female Healthcare Leader 2019 by the Indian Medical Association.
- International Women Entrepreneur Award 2019 by the IWEC Foundation.
- Healthcare Transformation Leader's Award at India's biggest event on innovation in healthcare, 'Healthcare in today's Digital India.'
- Women Power & Entrepreneurship Award 2007 by the FICCI Ladies Organization, Hyderabad Chapter.
- Top Woman Entrepreneur in ICT Sector 2005-06 by the Government of Andhra Pradesh.
- Young Manager of the Year Award 1998 by the Hyderabad Management Association.



Mr. Som Mittal

Mr. Som Mittal is a Distinguished Alumnus of the Indian Institute of Technology, Kanpur, and holds a Master's in Business Administration from the Indian Institute of Management, Ahmedabad.

With an illustrious career spanning over three decades in the IT and automotive sectors, Mr. Mittal has significantly contributed to the industry's growth and strategic vision of "Transform Business and Transform India." He is the past Chairman and President of NASSCOM, India's premier trade body for the IT and outsourcing industry, where he played a key role in shaping the sector's development.

He has been actively involved with multiple industry bodies, not-for-profit organizations, and academic institutions. Notably, he was a member of the Indian Prime Minister's Committee on National e-Governance and has served on the Boards of various corporate and academic institutions.

Mr. Mittal is also the Founding Chairman of the Patients For Patient Safety Foundation, an organization dedicated to engaging with patients to prevent medical harm and errors.

In recognition of his significant contributions to the industry and society, Mr. Mittal has received numerous citations and awards.



Annexure 5

Investment Proposals

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl.No.	Particulars	Description
1	Existing Capacity	<p>Apollo Hospitals Enterprise Limited has an existing portfolio of around 9,458 operational/ census beds (on a consolidated basis) as below:</p> <p>Hospitals beds – Owned – 8,025 census beds Hospital beds – O&M – 790 census beds Day Surgery and Birthing – 643 census beds</p>
2.	Existing Capacity utilisation	Of the 8,025 owned hospital beds, occupancy was at 68% in FY 2025 – 71% occupancy in Metros.
3.	Proposed Capacity Addition	<p>Purchase of a land parcel admeasuring 2.53 acres in Sarjapur, Bengaluru for setting up a 500 bedded multi-speciality hospital with an overall estimated cost for establishing the hospital being Rs 944 crores.</p> <p>Additionally, the Company will also be acquiring a 200 bedded hospital located in the vicinity of the land parcel identified for setting up the 500 bed greenfield hospital. The overall cost of acquiring the existing hospital facility (expandable to 200 beds immediately) and upgrading the existing hospital infrastructure is estimated to be Rs 285 crores</p> <p>This will bring the total number of New beds under expansion to over 3500 census beds. Please refer Annexure B for city wise details of Expansion announced.</p>
4.	Period within which the proposed capacity in Sarjapur, Bengaluru is to be added	<p>Existing hospital is expected to be re-launched in FY 2026 post completion of acquisition formalities – within 90-120 days of acquisition.</p> <p>Greenfield hospital will be established within the next 4 years</p>




Sl.No.	Particulars	Description
5.	Investment Required for hospital building and equipment	~ Rs 285 crores for existing hospital purchase, bed capacity expansion and re-launching ~ Rs 944 crores for Greenfield Hospital
6.	Mode of Financing	Through reserves and internal accruals
7.	Rationale	This initiative is in line with the strategy to expand footprint in identified strategic locations to drive continued business growth and cater to the increasing demand for quality healthcare services across the country




Annexure B

Hospital Expansion – Board Approved Plan:

Location	Nature	Total Beds	Census Beds
Expected commissioning : FY26			
Royal Mudhol, Pune	Hospital Asset Acquisition	400	325
Sonarpur, Kolkata	Hospital Asset Acquisition	270	220
Gachibowli, Hyderabad	Greenfield - Asset Light	375	300
Gurgaon, NCR	Hospital Asset Acquisition	510	420
Defence Colony, Delhi	Brownfield	42	27
Sarjapur-1	Acquisition - Leased facility	200	160
Malleswaram & Mysore Expansion	Brownfield	140	125
		1,937	1,577
Expected commissioning : In next 3 - 4years			
OMR, Chennai	Greenfield	600	500
Varanasi, U.P	Greenfield	400	300
Worli, Mumbai	Greenfield	575	500
Lucknow (Expansion), U.P	Brownfield	200	160
Sarjapur-2	Greenfield	500	400
Jubilee Hills (Expansion)	Brownfield	80	70
Secundrabad (Expansion)	Brownfield	80	70
		2,435	2,000
Total		4,372	3,577

Total Estimated project cost for the aforementioned projects is over Rs 8,000 crs of which over Rs 2,000 crs have been already incurred for land acquisition, security deposits, project development as applicable.

Balance project costs to be incurred over the next 3-4 years is approx. Rs 6,000 crs to be funded primarily through existing funds and Internal accruals.




//PRESS RELEASE //

Apollo hospitals announces significant expansion in Bengaluru in the Sarjapur micro-market through the addition of 700 beds in 2 stages, to establish a dominant presence in the South-Eastern part of the city, with large addressable market.

Stage 1: Acquisition of an existing 200-bed hospital facility on lease
Stage 2: Establishing a 500-bed greenfield hospital in close proximity

With the ongoing brownfield expansions in the city the total bed strength in Bengaluru will be ~ 1,500 beds.

These steps support the creation of a state-of-the-art, contemporary integrated healthcare offering in the attractive micro-market of Sarjapur, Bengaluru, while also facilitating an immediate start of services through the existing facility.

India, May 30, 2025: Apollo hospitals, India's largest vertically integrated healthcare provider, announced a major expansion today, to add 700 beds in the growing metropolitan market of Bengaluru, by establishing a 500 -bed greenfield hospital at Sarjapur on a land parcel of 2.53 acres which has been purchased and acquiring an existing 200-bed hospital facility proximal to the land parcel. Along with its existing multispecialty facilities at 3 premium locations in Bengaluru and its clinics network, this development is set to help Apollo Hospitals strengthen its position as a leading healthcare provider in the Bengaluru market with ~ 1500 beds post expansion.

Over the last 5 years, Apollo Hospitals has strengthened its clinical programs and gained significant market share in the city. This investment will help expand the network and leverage its brand strength in a new and attractive micro-market. **Sarjapur, in South-East Bengaluru, is within the fastest growing catchment, with affluent population and a thriving local community. It is a vital locale that links crucial localities such as Whitefield, Koramangala, and Electronic City seeing extensive residential and commercial developments.**

The greenfield hospital is expected to be operational in 4 years. Services from the 200-bed hospital can commence in 90-120 days post-acquisition.

The integrated 700-bed facility, with Comprehensive Cancer offering, is envisioned to redefine holistic health by integrating advanced diagnostic screening, state-of-the-art surgical care—including cutting-edge robotics—and comprehensive high-end therapies across specialties such as cardiology, oncology, gynaecology, neurology, orthopaedics, intensive care and more.



With Apollo Hospitals' proven expertise in these Centres of Excellence, and with its commitment to exceptional emergency and trauma services, the facility will be equipped with international-grade medical equipment along with highly skilled and experienced Doctors. Patients will receive world-class care at an accessible cost, with procedure costs anticipated at just one-tenth of those typically seen for similar treatments worldwide, making the hospital a trusted destination for quality and affordable healthcare.

With these additions, Apollo Hospitals now has plans to add over 4,300 capacity beds (Approximately 3,500 census / operational beds) over the next 4 years as per the table below.

Total Estimated project cost for the aforementioned projects is over Rs 8,000 crs of which over Rs 2,000 crs have been already incurred for land acquisition, security deposits, project development as applicable.

Balance project costs to be incurred over the next 3-4 years is approx. Rs 6,000 crs to be funded primarily through existing funds and Internal accruals.

Location	Nature	Total Beds	Census Beds	Project Cost (in Crs)	Balance Project Cost (in Crs)
Expected commissioning : FY26					
Royal Mudhol, Pune	Hospital Asset Acquisition	400	325	₹ 630	₹ 260
Sonarpur, Kolkata	Hospital Asset Acquisition	270	220	₹ 310	₹ 130
Gachibowli, Hyderabad	Greenfield - Asset Light	375	300	₹ 515	₹ 390
Gurgaon, NCR	Hospital Asset Acquisition	510	420	₹ 1,190	₹ 585
Defence Colony, Delhi	Brownfield	42	27	₹ 65	₹ 25
Sarjapur-1	Acquisition - Leased facility	200	160	₹ 285	₹ 278
Malleswaram & Mysore Expansion	Brownfield	140	125	₹ 170	₹ 165
		1,937	1,577	₹ 3,165	₹ 1,833
Expected commissioning : In next 3 - 4years					
OMR, Chennai	Greenfield	600	500	₹ 945	₹ 690
Varanasi, U.P	Greenfield	400	300	₹ 640	₹ 540
Worli, Mumbai	Greenfield	575	500	₹ 1,315	₹ 1,215
Lucknow (Expansion), U.P	Brownfield	200	160	₹ 320	₹ 235
Sarjapur-2	Greenfield	500	400	₹ 944	₹ 734
Jubilee Hills (Expansion)	Brownfield	80	70	₹ 220	₹ 220
Secundrabad (Expansion)	Brownfield	80	70	₹ 545	₹ 545
		2,435	2,000	₹ 4,929	₹ 4,179
Total		4,372	3,577	₹ 8,094	₹ 6,012

Commenting on this milestone, **Dr Prathap C Reddy, Founder & Chairman, Apollo Hospitals**, said,

"Since its inception over 40 years ago, Apollo Hospitals has embodied the essence of Indian healthcare on a global stage. With each new facility, we reaffirm our commitment to providing the highest standards of treatment to our people. Our mission is to make world-class healthcare accessible to every Indian, and our expansion strategy is a testament to that promise. By bringing in leading clinicians and the finest technology, we aim to elevate




healthcare standards and set new benchmarks. I am thrilled to announce this new chapter in our journey to advance healthcare for all.”

“With our expansion in Bengaluru, we’re taking a significant step forward in our commitment to making top-quality healthcare accessible across India.” said **Ms Suneeta Reddy, Managing Director, Apollo Hospitals.** “For over four decades, we’ve been laser-focused on advancing healthcare practices in India. These new facilities strengthen our footprint in strategic locations, catering to the growing demand for excellence in healthcare. They will serve as touchpoints for next-generation healthcare practices and treatments that set a new benchmark in the industry, ensuring the best is within reach for all. With these two additional expansions, we now have plans to increase our overall capacity beds by over 4,300 over the next 4 years beginning FY26. ”

About Apollo Hospitals

Apollo revolutionized healthcare when Dr. Prathap Reddy opened the first hospital in Chennai in 1983. Today, Apollo is the world’s largest integrated healthcare platform with over 10,400 beds across 74 hospitals, 6,600+ pharmacies, 264 clinics, 2,182 diagnostic centres, and 800+ telemedicine centres. It is one of the world’s leading cardiac centers, having performed over 3,00,000 angioplasties and 2,00,000 surgeries. Apollo continues to invest in research and innovation to bring the most cutting-edge technologies, equipment, and treatment protocols to ensure patients have access to the best care in the world. Apollo’s 1,20,000 family members are dedicated to delivering exceptional care and leaving the world better than we found it.

For further details, log onto: www.apollohospitals.com



A handwritten signature in blue ink, consisting of stylized initials and a horizontal line underneath.

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



30th May 2025

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code - 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra - Kurla Complex
Bandra (E)
Mumbai - 400 051.
Scrip Code-
APOLLOHOSP
ISIN INE437A01024

Dear Sir,

Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that Deloitte Haskins & Sells (Firm Registration No. 117366 W/W 100018), Chartered Accountants, Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on the Audited Financial Results (both standalone and consolidated) of the Company for the year ended 31st March 2025.

Kindly take on record the same.

Thanking You

Yours faithfully
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN
Sr. VICE PRESIDENT - FINANCE
AND COMPANY SECRETARY



IS/ISO 9001 : 2000

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 2829 0956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com